



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.

Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated February 28, 2018**

To,  
National Stock Exchange of India Limited  
Bombay Stock Exchange Limited  
Symbol: NSE: GRANULES; BSE: 532482

**Sub: Receipt of Establishment Inspection Report (EIR) by Granules Pharmaceuticals, Inc. facility from US FDA -Reg.**

**Ref: Our letter dated 11<sup>th</sup> December 2017 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Please be informed that, US FDA has issued Establishment Inspection Report (EIR) for Granules Pharmaceuticals, Inc. facility, a wholly-owned foreign subsidiary of the Company located in Chantilly, Virginia, USA.


This facility was inspected by US FDA in December 2017 and there was one (1) observation during the inspection. The company has responded to the observation within the stipulated timeframe.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

**For GRANULES INDIA LIMITED**



**CHAITANYA TUMMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)**